SGMOQ · Sangamo Therapeutics, Inc
$0.16
-0.01 (-5.23%)
At close · Aug 18
Going-concern doubt
— flagged May 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“There is substantial doubt about our ability to continue to operate as a going concern. We will need substantial additional funding in the very near term to execute our operating plan and to continue to operate as a going concern.”View the 10-Q filed May 14, 2026
Market Cap
$69.72M
Shares
414.29M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.16
Open$0.15
Day$0.15–0.16
52W close$0.04–0.74
Avg vol 30d3.5M
Short int10.3M · 2.5% float · 2.3d
Short vol72%
Last earningsMay 14, 2026
DataJan 2020–Aug 2026
Filing10-Q · May 14
Up next
Next earnings call
Sep 8, 2026
Est · unconfirmed
· in 3 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 14, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.8 · calm
Equity put/call 0.64
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−46%
below
Price vs 50-day avg
+57%
above
RSI (14)
69
neutral
MACD trend
Positive
52-week position
17%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+128%
trailing
6-month return
−66%
trailing
YTD return
−62%
this year
Relative strength
−77%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Distributing
-94% holders QoQ · +2 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.49% of float · ▼ -1.3% MoM · 2.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
7 holders — near 3-yr low, contrarian setup
Squeeze score
71
high risk · 0–100
Fundamentals
Revenue growth
+89%
Y/Y
EPS growth
+10%
Y/Y
Free cash flow
$-97.3M
Balance sheet
$20.9M
net cash
Quant / Vol
risk profile
Volatility
161%
annualized · 1-yr
Max drawdown
−95%
past year
ATR
14.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Mar 30, 2026
GAAP total operating expenses
· 2026
$120M – $140M
Non-GAAP total operating expenses
· 2026
$110M – $120M
Prior guidance
period ended
· from the 8-K filed Nov 6, 2025
Total operating expenses
· 2025
$135M – $155M
Non-GAAP total operating expenses
· 2025
$125M – $145M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−46%
Bearish
Price vs 50-day avg
+57%
Bullish
RSI (14)
69
Neutral
MACD trend
Positive
Bullish
52-week position
17%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Distributing
-94% holders QoQ · +2 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.49% of float · ▼ -1.3% MoM · 2.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
7 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $0
Now $0 · 17%
Range high $1
vs 200-day avg -46%
vs 50-day avg +57%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Non-GAAP operating expenses non-GAAP | $31.7M | Three Months Ended March 31, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SGMOQ
this stock
Sangamo Therapeutics, Inc
|
$69.72M | -62.0% | +88.6% | — | 2.5% |
|
ONC
BeOne Medicines Ltd.
|
$535.83B | +21.5% | +22179.2% | 823.9 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.88B | +16.5% | +46.2% | 30.8 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$84.27B | +5.0% | +20.8% | 20.3 | 3.3% |
|
ARGX
Argenx SE
|
$61.75B | +18.1% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SGMOQ | +10.0% | +127.9% | -66.1% | +127.9% | -62.0% |
| SPY | -0.4% | +2.6% | +10.7% | +2.7% | +12.5% |
| vs SPY | +10.4% | +125.3% | -76.8% | +125.1% | -74.6% |